Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements (Details)

v3.19.3
Sponsored Research and License Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2019
Sep. 30, 2019
Jan. 31, 2019
Oct. 31, 2018
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2019
Kissei              
Collaborations              
Upfront payment received       $ 33,000,000      
Contingent payments       $ 147,000,000      
Revenue recognized           $ 30,600,000  
Grifols              
Collaborations              
Upfront payment received     $ 30,000,000       $ 5,000,000
Deferred revenue related to upfront payment   $ 25,400,000     $ 25,400,000   25,400,000
Grifols | Research Services              
Collaborations              
Revenue recognized         71,000   215,000
Grifols | Commercial Milestones              
Collaborations              
Contingent payments     297,500,000        
Aclaris              
Collaborations              
Collaborative payment received   4,000,000          
Revenue recognized         4,000,000   4,000,000
Celgene              
Collaborations              
Collaborative payment received   3,800,000          
Revenue recognized         3,800,000   3,800,000
fostamatinib | Kissei              
Collaborations              
Deferred revenue related to upfront payment   $ 1,400,000     1,400,000   1,400,000
Revenue recognized         $ 1,400,000   $ 1,600,000
fostamatinib | Grifols | Prior written notice following the second anniversary of the first MAA approval of fostamatinib in Europe and Turkey              
Collaborations              
Right to terminate agreement within number of months after second anniversary             6 months
fostamatinib | Grifols | Terminated agreement upon prior written notice within six months after second anniversary of agreement              
Collaborations              
Contingent upfront fee, refund requirement     25,000,000        
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP              
Collaborations              
Contingent payments $ 20,000,000   $ 20,000,000        
fostamatinib | Grifols | Maximum              
Collaborations              
Royalty payment as a percentage of net sales     30.00%